Ann: Medical Cannabis Clinical Study Commencing, page-2

Medical Cannabis Clinical Study Commencing with World Leading Epilepsy Physicians Development of Proprietary Epilepsy Formula for MXC Pharmaceuticals

• MGC Pharmaceuticals to commence a clinical study to assess the efficacy of a medicinal cannabis formulation in children and adolescents with treatmentresistant epilepsy

• Study brings together two globally renowned epilepsy experts, Dr David Neubauer and MXC Advisory Board member, Professor Uri Kramer to oversee the clinical test program

• Over 65 volunteers already recruited to the 6-week study, with a large pool of potential volunteers that have expressed an interest in participating

• Results from the study will be instrumental in the Company’s development of its own proprietary pharmaceutical grade product for epilepsy treatments

• Potential for future clinical studies globally to use Company’s own proprietary formula and dosage

• The registration and sale of a pharmaceutical product for the treatment of epilepsy presents a significant commercial opportunity